{
    "id": 13135,
    "fullName": "EGFR E709X",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR E709X indicates any Egfr missense mutation that results in the replacement of the glutamic acid (E) at amino acid 709 by a different amino acid. EGFR E709 mutations are considered hotspot mutations (PMID: 18372921).",
            "references": [
                {
                    "id": 3762,
                    "pubMedId": 18372921,
                    "title": "EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18372921"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "E709X",
    "createDate": "10/15/2015",
    "updateDate": "02/28/2020",
    "referenceTranscriptCoordinates": {
        "id": 135601,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55173984_55173986",
        "cDna": "c.2125_2127",
        "protein": "p.E709",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11156,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, non-small cell lung cancer patients harboring EGFR E709 mutations demonstrated a response rate of 66.66% and a median progression-free survival of 3.1 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",
            "molecularProfile": {
                "id": 13298,
                "profileName": "EGFR E709X"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 9121,
                    "pubMedId": null,
                    "title": "Clinical efficacy of icotinib in patients with advanced non-small cell lung cancer harboring EGFR exon 18, 20 and 21 uncommon mutations.",
                    "url": "http://abstracts.asco.org/199/AbstView_199_186649.html"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3360,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients harboring an EGFR E709 mutation (PMID: 26354527).",
            "molecularProfile": {
                "id": 13298,
                "profileName": "EGFR E709X"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3736,
                    "pubMedId": 26354527,
                    "title": "Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26354527"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20688,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, MET amplification was identified in a non-small cell lung cancer patient harboring an EGFR E709 mutation with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35283,
                "profileName": "EGFR E709X MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13298,
            "profileName": "EGFR E709X",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35283,
            "profileName": "EGFR E709X MET amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135601,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55173984_55173986",
            "cDna": "c.2125_2127",
            "protein": "p.E709",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}